Multiple Myeloma: Primary Bone Tumor with Systemic Manifestations

Neurosurgery Clinics of North America

Volumn 19, Issue 1, 2008, Pages 31-40

  Bilsky, Mark H ^a,b   Azeem, Syed ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; POLY(METHYL METHACRYLATE); ZOLEDRONIC ACID;

ARTHRALGIA; BONE NECROSIS; BONE TUMOR; CLINICAL FEATURE; COMORBIDITY; COMPRESSION FRACTURE; DECOMPRESSION SURGERY; DIAGNOSTIC IMAGING; DRUG COST; FLU LIKE SYNDROME; HUMAN; JAW DISEASE; LABORATORY TEST; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PLASMA CELL DYSCRASIA; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SYSTEMIC DISEASE; TREATMENT FAILURE; TREATMENT INDICATION; VERTEBRA BODY;

DIAGNOSTIC IMAGING; DIPHOSPHONATES; HUMANS; MULTIPLE MYELOMA; NEUROSURGICAL PROCEDURES; OSTEOLYSIS; SPINAL CORD COMPRESSION; SPINAL FRACTURES; SPINAL NEOPLASMS; SPINE;

EID: 37349087172     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2007.09.001     Document Type: Review

References (40)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Kyle R.A. Multiple myeloma: review of 869 cases. Mayo Clin Proc 50 1 (1975) 29-40
3. Richardson P.G., Mitsiades C., Schlossman R., et al. New drugs for myeloma. Oncologist 12 6 (2007) 664-689
4. Attai M., Harousseau J.L., Stoppa A.M., et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroup Francais du Myelome. N Engl J Med 335 (1996) 91-97
5. Child J.A., Moragn G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
6. Stern J.M., Sullivan K.M., Ott S.M., et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant 7 5 (2001) 257-264
7. Wu S., Dahut W.L., and Gulley J.L. The use of bisphosphonates in cancer patients. Acta Oncol 46 5 (2007) 581-591
8. Nakagawa N., Kinosaki M., Yamaguchi K., et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253 2 (1998) 395-400
9. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 2 (1997) 309-319
10. Kong Y.Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 6717 (1999) 315-323
11. Dougall W.C., Glaccum M., Charrier K., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 13 18 (1999) 2412-2424
12. Pearse R.N., Sordillo E.M., Yaccoby S., et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98 20 (2001) 11581-11586
13. Giuliani N., Bataille R., Mancini C., et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98 13 (2001) 3527-3533
14. Sezer O., Heider U., Zavrski I., et al. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101 6 (2003) 2094-2098
15. Boyden L.M., Mao J., Belsky J., et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346 20 (2002) 1513-1521
16. Mukhopadhyay M., Shtrom S., Rodriguez-Esteban C., et al. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell 1 3 (2001) 423-434
17. Grotewold L., and Ruther U. The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J 21 5 (2002) 966-975
18. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 26 (2003) 2483-2494
19. Zamagni E., Nanni C., Patriarca F., et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 92 1 (2007) 50-55
20. Schmidt G.P., Reiser M.F., and Baur-Melnyk A. Whole-body imaging of the musculoskeletal system: the value of MR imaging. Skeletal Radiol (2007) in press
21. Johnston C., Brennan S., Ford S., et al. Whole body MR imaging: applications in oncology. Eur J Surg Oncol 32 3 (2006) 239-246
22. Hur J., Yoon C.S., Ryu Y.H., et al. Efficacy of multidetector row computed tomography of the spine in patients with multiple myeloma: comparison with magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography. J Comput Assist Tomogr 31 3 (2007) 342-347
23. Breyer III R.J., Mulligan M.E., Smith S.E., et al. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol 35 9 (2006) 632-640
24. Nanni C., Zamagni E., Farsad M., et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 33 5 (2006) 525-531
25. Nanni C., Zamagni E., Cavo M., et al. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol 5 (2007) 68
26. Terpos E., and Rahemtulla A. Bisphosphonate treatment for multiple myeloma. Drugs Today 40 1 (2004) 29-40
27. Berenson J.R., Lichtenstein A., Porter L., et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16 2 (1998) 593-602
28. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7 5 (2001) 377-387
29. McCloskey E.V., MacLennan I.C., Drayson M.T., et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100 2 (1998) 317-325
30. McCloskey E.V., Dunn J.A., Kanis J.A., et al. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113 4 (2001) 1035-1043
31. Kyle R.A., Yee G.C., Somerfield M.R., et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25 17 (2007) 2464-2472
32. Zervas K., Verrou E., Teleioudis Z., et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134 6 (2006) 620-623
33. Bilsky M., and Smith M. Surgical approach to epidural spinal cord compression. Hematol Oncol Clin North Am 20 6 (2006) 1307-1317
34. Rao G., Ha C.S., Chakrabarti I., et al. Multiple myeloma of the cervical spine: treatment strategies for pain and spinal instability. J Neurosurg Spine 5 2 (2006) 140-145
35. Patchell R.A., Tibbs P.A., Regine W.F., et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366 9486 (2005) 643-648
36. Sachs D.C., Inamasu J., Mendel E.E., et al. Transoral vertebroplasty for renal cell metastasis involving the axis: case report. Spine 31 24 (2006) E925-E928
37. Dudeney S., Lieberman I.H., Reinhardt M.K., et al. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 20 9 (2002) 2382-2387
38. Cotten A., Dewatre F., Cortet B., et al. Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up. Radiology 200 2 (1996) 525-530
39. Hentschel S.J., Burton A.W., Fourney D.R., et al. Percutaneous vertebroplasty and kyphoplasty performed at a cancer center: refuting proposed contraindications. J Neurosurg Spine 2 4 (2005) 436-440
40. Chakrabarti I., Burton A.W., Rao G., et al. Percutaneous vertebroplasty of a myelomatous compression fracture in the presence of previous posterior instrumentation. Report of two cases. J Neurosurg Spine 5 2 (2006) 168-171